Results 51 to 60 of about 15,919 (234)

Characteristics in propensity score-matched DOAC vs warfarin users and DOAC vs DOAC.

, 2019
Characteristics in propensity score-matched DOAC vs warfarin users and DOAC vs DOAC.
Anagha Nadkarni (4801347), Jack Mardekian (88174), Xiaoyan Li (117291), Alessandra B. Garcia Reeves (6503819), Amol Dhamane (6503822), Lisa Rosenblatt (734647), Allison Keshishian (2582335), Manuela Di Fusco (6503825), Keith Friend (4801350), Xianying Pan (4801356), Alpesh Amin (4163710), Xuemei Luo (65327), Huseyin Yuce (5236100)   +12 more
core   +1 more source

Characteristics of renal transplant recipients on standard dose and dose-reduced DOAC.

, 2023
Characteristics of renal transplant recipients on standard dose and dose-reduced DOAC.
Elisabeth S. Lim (15503366), Christine Firth (15503357), Mira T. Keddis (4246462), Nan Zhang (46264), Fadi Shamoun (15503360), Michael Apolinario (15503363)   +5 more
core   +1 more source

Development and Validation of an HPLC-MS/MS Method for Quantification of Apixaban in Human Plasma

Разработка и регистрация лекарственных средств
Introduction. Apixaban is an anticoagulant used in a number of thromboembolic diseases with an improved benefit-to-risk ratio, according to multiple clinical studies. Due to the prescription of apixaban as antithrombotic therapy in patients with COVID-19,
U. D. Filonova, P. K. Karnakova, K. K. Karnakova, M. O. Popova, A. A. Popova, O. A. Archakova, T. N. Komarov, I. E. Shohin   +7 more
doaj   +1 more source

Need to determine the residual concentrations of direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter implantation of the aortic valve

Атеротромбоз, 2023
Introduction. Lengthening the period of direct oral anticoagulant (DOAC) withdrawal before intervention is not allowed. Chronic kidney disease (CKD), impaired liver function, extremely low or high body mass, chronic heart failure (CHF), and age > 90 ...
A. I. Staroverova, E. S. Kropacheva, A. B. Dobrovolsky, E. V. Titaeva, E. P. Panchenko   +4 more
doaj   +1 more source

Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases

BMC Nephrology, 2022
Background Nephrotic syndrome (NS) is associated with increased risk of thromboembolic events (TE) adding to the morbidity and mortality. International guidelines recommend prophylactic anticoagulation in patients with NS and high risk of TE, but no ...
Sarah Kelddal, Anne-Mette Hvas, Erik Lerkevang Grove, Henrik Birn   +3 more
doaj   +1 more source

Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta‐Analysis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Intravenous thrombolysis (IVT) is an effective stroke therapy that remains underused. Currently, the use of IVT in patients with recent direct oral anticoagulant (DOAC) intake is not recommended.
Malik Ghannam, Mohammad AlMajali, Milagros Galecio‐Castillo, Abdullah Al Qudah, Farid Khasiyev, Mahmoud Dibas, Dana Ghazaleh, Juan Vivanco‐Suarez, Cristian Morán‐Mariños, Mudassir Farooqui, Aaron Rodriguez‐Calienes, Prateeka Koul, Hannah Roeder, HyungSub Shim, Edgar Samaniego, Enrique C. Leira, Harold P. Adams, Santiago Ortega‐Gutierrez   +17 more
doaj   +1 more source

Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy

British Journal of Clinical Pharmacology, EarlyView.
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou, Alexander T. Cohen, Lucy Vernon, Victoria Collings, Ubonphan Chaichana, Natasha Moore, Hamda Jibril, Li Wei, Nicola Kumar, Karen A. Breen, Andrew J. Doyle   +10 more
wiley   +1 more source

Comparative treatment effects of direct oral anticoagulants versus warfarin for nonvalvular atrial fibrillation in clinical practice vary over time due to channelling

British Journal of Clinical Pharmacology, EarlyView.
Aim Temporal shifts in patient characteristics can influence comparative treatment effects within a certain indication. We investigated patient characteristics and comparative effectiveness and safety for direct oral anticoagulants (DOACs) and warfarin over the time period where DOACs replaced warfarin as preferred stroke prophylaxis in patients with ...
Raoul B. L. J. van den Hemel, Aernoud T. L. Fiolet, Magdalena A. Gamba, Patrick C. Souverein, Olaf H. Klungel, Lourens T. Bloem, Sophie H. Bots   +6 more
wiley   +1 more source

Detailed and overall costs of DOAC and VKA treatments for 3 months.

, 2023
VKA, vitamin K antagonists; DOAC, direct oral anticoagulants; GP, General practitioner; CP, coordinating physician.
Sahondranirina Rakotoniary (15183119), Ariane Vidal (15183125), Antonin Dacasa Cortes (15183098), George Pisica–Donose (15183086), Catherine Bayle (15183104), Ion Berechet (15183095), Bastien Genet (14098095), Mihai Badescu (15183107), Matthieu Piccoli (15183089), Isabelle Merlier (15183116), Jean-Sébastien Vidal (249552), Olivier Hanon (482564), François Catelain (15183110), Stéphane Bouee (9867116), Lynda Kermeche (15183113), Stefan Berechet (15183092), Sabri Atsamena (15183101), Valérie Savin (15183122)   +17 more
core   +1 more source

[Contraindications to DOACs in atrial fibrillation].

Nederlands tijdschrift voor geneeskunde, 2020
Sometimes there is doubt as to whether or not anticoagulants should be initiated, and if so which ones, in patients with atrial fibrillation and advanced age, increased frailty, or fall risk, kidney, or liver impairment, alcohol abuse, uncontrolled hypertension, or a history of major bleeding.
Vries, T.A.C. de, Hemels, M.E.W., Pisters, R., Jansen, R., Groot, J.R. de   +4 more
openaire   +3 more sources